<DOC>
	<DOCNO>NCT02907294</DOCNO>
	<brief_summary>To assess safety tolerability five dos PBF-999 ( 160 mg 320mg ) repeat ( 8 day ) single daily oral dose administration young male female healthy subject .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability Pharmacokinetic Profile PBF-999 `` After Multiple Oral Doses '' Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Healthy male female subject , 1845 year ( inclusive ) age time enrollment . Females must nonchildbearing potential ( i.e. , surgically sterile ) use contraceptive measure ( nonhormonal ) condom , diaphragm cervical/vault cap spermicide 28 day postadministration . Males agree abstain sexual intercourse female partner agree use condom spermicide , addition female partner use contraceptive measure 28 day postadministration . Clinically acceptable blood pressure pulse rate supine stand position . Blood pressure pulse measure minimum 3 minute rest . Body weight within normal range ( Quetelet 's index 19 26 ) express weight ( kg ) / height ( m2 ) . Able understand nature study comply requirement . Free acceptance participate study obtains sign informed consent form approve Ethics Committee Hospital ( CEIC ) . History serious adverse reaction hypersensitivity drug . Presence history allergy require acute chronic treatment ( except seasonal allergic rhinitis ) . Background clinical evidence chronic disease . Acute illness two week drug administration . Having undergone major surgery previous 6 month . Smokers ( refrain tobacco usage , include smokeless tobacco , nicotine patch , etc. , 6 month prior administration study medication History alcohol dependence drug abuse last 5 year daily consumption alcohol &gt; 40 g men 24 gr/day woman high consumption stimulate beverage ( &gt; 5 coffee , tea coca cola drinks/ day ) Abnormal physical finding clinical significance screen examination baseline would interfere objective study . Need prescription medication within 14 day prior administration drug non prescription medication herbal medicine within 7 day prior administration drug . Participation clinical trial previous 90 day investigational drug commercially available drug test . Having donate blood 4 week period inclusion study . Existence surgical medical condition might interfere absorption , distribution , metabolism excretion drug , i.e . impaired renal hepatic function , diabetes mellitus , cardiovascular abnormality , chronic symptom pronounce constipation diarrhea condition associate total partial obstruction urinary tract . 12 lead ECG obtain screen PR ≥ 220 msec , QRS ≥120 msec QTc ≥ 440 msec , bradychardia ( &lt; 50 bpm ) clinically significant minor ST wave change abnormal change screen ECG would interfere measurement QT interval . Symptoms significant somatic mental illness four week period precede drug administration . History hepatitis HBV / HCV / positive serology result indicate presence hepatitis B surface antigen / detectable HCV ribonucleic acid ( RNA ) . Positive result HIV serology . Females positive result pregnancy test breastfeed Clinically significant abnormal laboratory value ( determine Principal Investigator ) screen evaluation . Positive result drug screen period day start treatment period . A minimum list drug screen include Amphetamines , Cocaine , Ethanol , Opiates , Cannabinoids Benzodiazepines ( positive result may repeat discretion Principal Investigator ) . Known hypersensitivity study drug composition galenical form History psychiatric disease epileptic seizure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>PDE10 inhibitor</keyword>
	<keyword>phosphodiesterase 10 inhibitor</keyword>
	<keyword>Huntington 's disease</keyword>
	<keyword>psychiatric disorder</keyword>
</DOC>